It is well established that focusing on diversity in clinical trials is essential for developing therapies that are safe and effective for different patient populations.
Editor-in-chief Jonah Comstock welcomes back returning guest Dr Jennifer Jones-McMeans, divisional vice president for global affairs for Abbott’s vascular business.
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio